Karine Briot
Overview
Explore the profile of Karine Briot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
1834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marie-Eva P, Pickering M, Souberbielle J, Jean-Claude S, Boutten A, Anne B, et al.
Joint Bone Spine
. 2025 Feb;
92(3):105858.
PMID: 39978583
Advantages and disadvantages of intermittent versus daily vitamin D supplementation especially in adults with or at risk of osteoporosis are discussed by the Osteoporosis Research and Information Group (GRIO). The...
2.
Haffner D, Emma F, Seefried L, Hogler W, Javaid K, Bockenhauer D, et al.
Nat Rev Nephrol
. 2025 Feb;
PMID: 39905262
No abstract available.
3.
Haffner D, Emma F, Seefried L, Hogler W, Javaid K, Bockenhauer D, et al.
Nat Rev Nephrol
. 2025 Jan;
PMID: 39814982
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by...
4.
Kamenicky P, Briot K, Munns C, Linglart A
Lancet
. 2024 Aug;
404(10455):887-901.
PMID: 39181153
X-linked hypophosphataemia is a genetic disease caused by defects in the phosphate regulating endopeptidase homolog X-linked (PHEX) gene and is characterised by X-linked dominant inheritance. The main consequence of PHEX...
5.
Lecoq A, Schilbach K, Rocher L, Trabado S, Briot K, Herrou J, et al.
Eur J Endocrinol
. 2024 Aug;
191(2):156-165.
PMID: 39120742
Objectives: X-linked hypophosphatemia (XLH) is characterized by increased concentrations of circulating fibroblast growth factor 23 (FGF-23) resulting in phosphate wasting, hypophosphatemia, atypical growth plate and bone matrix mineralization. Epidemiologic studies...
6.
Veronese N, Briot K, Guanabens N, Albergaria B, Alokail M, Al-Daghri N, et al.
Aging Clin Exp Res
. 2024 Aug;
36(1):167.
PMID: 39120740
Bone forming agents, also known as anabolic therapies, are essential in managing osteoporosis, particularly for patients at very high-risk of fractures. Identifying candidates who will benefit the most from these...
7.
Herve A, Gadion M, Herrou J, Izart M, Linglart A, Cohen-Solal M, et al.
J Clin Endocrinol Metab
. 2024 Jun;
PMID: 38864457
Context: X-linked hypophosphatemia (XLH) is a rare genetic bone disease affecting both children and adults, with oral manifestations such as spontaneous dental infections. The main treatments for XLH are conventional...
8.
Boot A, Ariceta G, Beck-Nielsen S, Brandi M, Briot K, Collantes C, et al.
Ther Adv Chronic Dis
. 2024 May;
15:20406223241247643.
PMID: 38764445
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis. Burosumab is a recombinant...
9.
Chevalier K, Hamroun S, Bitoun S, Henry J, Roux C, Briot K, et al.
Bone Rep
. 2024 Apr;
21:101755.
PMID: 38577249
Multiple myeloma (MM) frequently causes vertebral fractures (VF). Some are lytic lesions and others have the aspect of benign osteoporotic fractures not requiring anti-myeloma treatment. We explored outcome of these...
10.
Roux C, Briot K
Lancet Rheumatol
. 2024 Jan;
2(2):e110-e119.
PMID: 38263657
The number of fractures related to osteoporosis is expected to increase dramatically in the next few decades because of an increase in the number of elderly patients at high risk...